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ABSTRACT
Antibodies are now indispensable tools for all
areas of cell biology and biotechnology as well as
for diagnosis and therapy. Antigen-specific single
immunoglobulin variable domains that bind to
native antigens can be isolated and manipulated
using yeast intracellular antibody capture technol-
ogy but converting these to whole monoclonal anti-
body requires that complementary variable domains
(VH or VL) bind to the same antigenic site. We
describe a simple approach (CatcherAb) for specific
isolation of such complementary single domains
allowing the constitution of functional Fv, forming
the basis of antigen-specific whole immunoglobulin
and thus antibody production. We illustrate this
approach by developing high-affinity Fv from
single variable domains binding to RAS and LMO2
oncogenic proteins.
INTRODUCTION
The speed and versatility with which monoclonal antibo-
dies (human or mouse) can be isolated has increased since
the ﬁrst Ko ¨ hler–Milstein description (1), partly due to
phage display technologies that have rendered isolation
of single-chain Fv (scFv, comprising linked VH and VL
segments) (2) or single V domains achievable (3,4). The
importance of high-quality reagents in a number of cell
and molecular biology applications (5) necessitates the
development of convenient technologies that can be
applied in basic research laboratories as tools but also
for clinical use where mouse–human chimaeric monoclo-
nal antibodies (6,7) or humanized versions (8) are making
a major impact. A number of important laboratory tech-
niques also require antibodies that can bind to native,
intracellular proteins, such as ﬂow cytometric detection
of intracellular proteins, using cell permeabilization
(9), and immunoprecipitation-based methods including
pull-downs, analysis of protein complexes and chromatin
immunoprecipitation analysis.
Single-domain antibody (Dab) libraries have provided
sources of antibody fragments that can be used as antibody
reagents (10) or as intracellular antibody fragments (11).
Furthermore, single domains that bind to native proteins
can be preferentially isolated using in vivo library screening
in the yeast intracellular antibody capture (IAC) technol-
ogy (12,13), because the target protein is expressed inside
the cell within a normal cellular environment. In addition,
the method can detect previously silent epitopes that may,
for instance, fall within small clefts in antigen targets.
Whilst the isolation of single-domain antibodies has
been made simple by screening with phage display and
yeast, obtaining compatible pairs of VH and VL segments
that bind at the same epitopic region requires additional
steps. Furthermore, scFv obtained by phage display do not
always provide complementary binders to a single epitopic
region because of the way that the scFv are built from
separate VH and VL segments. Ideally, engineering an
scFv from single domains for binding native proteins
in vivo could involve screening libraries of V regions to
select a single domain of choice followed by a second
screen that depends on the co-location of VH and VL
on the antigen surface. We describe such a method
(CatcherAb) for drawing together diverse single domains
(VH and VL) into a high-aﬃnity Fv format that can form
the basis of a complete antibody (which can have any tag
required, be of any class required and of any species). The
method involves the mandatory interaction of VH and VL
domains in contact with native antigens as the basis for
selection. We illustrate this with the selection and engineer-
ing of two distinct Fv that speciﬁcally bind to their anti-
genictarget (namely oncogenic RAS or LMO2) at the same
epitopic location. The ﬁnal scFvs have nanomolar aﬃnity.
MATERIALS AND METHODS
Plasmids
The yeast vectors, pBTM116-HRAS(G12V) and pVP16,
are described in detail elsewhere (13). pBTM116-dLMO2
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LMO2 cDNA (14) into EcoRI-SalI sites of pBTM116
vector. The pCatcher plasmid is described in detail in
Supplementary Figure S1. The mammalian expression
vectors, pM-HRAS(G12V) (Gal4-DBD fusion bait) and
the pEFVP16 (VP16-AD fusion prey), are described else-
where (13). pM-dLMO2 was constructed by cloning the
N-terminal truncated LMO2 cDNA into EcoRI-SalI sites
of the pM vector. pEF/myc/nuc/VH was constructed
by sub-cloning the anti-RAS VH#6 (13) or anti-LMO2
VH#576 (TT and THR, unpublished results) into the
NcoI and NotI sites of pEF/myc/nuc (Invitrogen). All
constructs were sequenced to conﬁrm in-frame fusion of
the inserts with signal peptide or fusion partners.
Yeastsingle-domain VLlibrary construction
Single-domain human VL libraries were constructed in the
yeast prey vector pVP16. For the initial library construc-
tion for step-one screens (Figure 1A), a mixture of VL
DNA fragments were PCR ampliﬁed from the human
scFv phage libraries I or J (15) as template with the pri-
mers SﬁVLF and pHENSeqR (all primer sequences used
in PCR are shown in Supplementary Table S1). The PCR
products were sub-cloned into the SﬁI-NotI sites of
pVP16. The constructed VL libraries are composed of a
single framework for Vk1 and diversiﬁed at two residues
in CDR2 and ﬁve residues in CDR3 of VL domain
(Figure 1B). The size of the VL libraries was 3.310
6
(VL-I library from scFv phage library I) and 1.110
6
(VL-J from library J), respectively. The sequences of 10
randomly picked clones derived from both VL-I and VL-J
were sequenced for quality control and two of the 10
clones in each library had in-frame translational stop
codons or frame shifts.
For construction of the VL library for an optional
second-round screening (Figure 1A, Step 1, optional), pos-
itive clones from initial screenings of the VL library were
used for randomization of the CDR1 region by PCR muta-
genesis as described elsewhere (16). For the anti-RAS
screen, two PCRs were performed with the pairs of prim-
ers: sFvVP16F and VLCDR1R; or VP162R and
rdmVLCDR1F. The ampliﬁed DNA fragments were
puriﬁed and assembled using a second PCR reaction
involving the primers sFvVP16F and VP162R (16). The
randomizing CDR1 VL fragment was sub-cloned into
the SﬁI-NotI sites of pVP16. The size of the second VL
library for RAS screening was 1.210
6. Clones were
randomly picked from the library, plasmids prepared and
sequenced to verify the insert and randomization CDRs.
CatcherAb yeast screening ofhuman VL Dablibraries
Screening of the human VL single-domain libraries was
performed essentially according to the protocol of IAC
technology as described (12,13). First, 2.5mg each of
pBTM116 and pCatcher plasmid was transformed into
the L40-ura3 yeast strain (Invitrogen) using lithium ace-
tate transformation and the transformed yeast grown on
plates lacking tryptophan (Trp) and uracil (Ura) to estab-
lish yeast L40-ura3 clones stably expressing LexA-antigen
(Ag) and VH. Five hundred micrograms of a pVP16-VL
library were transfected into the above yeast host and pos-
itive clones selected on plates lacking Trp, leucine (Leu),
Ura and histidine (His). To identify human VL with high-
est aﬃnity for binding to antigen in the presence of VH,
yeast transformants were plated on selective medium con-
taining progressively increased concentrations of 3-amino-
1,2,4-triazole (3-AT) (Sigma) (3-AT inhibits his3 activity
in a dose-dependent manner). The plates were incubated
at 308C for 5–9 days (depending on the concentration
of 3-AT). The clones that reached >3mm in size were
counted, and 40 clones were randomly selected from the
plate containing the highest concentration of 3-AT. The
VL-VP16 clones were rescued, re-transformed into yeast
L40-ura3 expressing LexA-Ag bait with or without VH
and assessed for growth on plates lacking His and for
b-gal activation. Following these assays, the relevant
human VL segments were sequenced.
ATF-2-VP16 (11), cRAF-RBD (RAS-binding
domain of cRAF)-VP16, Y13-293 (scFv derived from
a anti-RAS rat monoclonal antibody)-VP16 (17) and
VH#6-VP16 were used as positive or negative controls
for binding speciﬁcity.
Mammalian transfection assays
Chinese Hamster Ovary (CHO) cells and derived CHO-
GFP reporter cells (11) were grown in a-minimal essential
medium (Invitrogen) with 10% FCS, penicillin and strep-
tomycin. To establish a CHO-GFP stable line expressing
Gal4DBD-HRAS(G12V) bait, cells were co-transfected
with pM-HRAS(G12V) plus SV40-neomycin (from pEF/
myc/nuc) using lipofectamine (Invitrogen) and selected in
medium containing 1mg/ml G418 and 0.3mg/ml hygro-
mycin B for 1 week. One hygromycin–neomycin resistant
clone (CHO-GFP-RAS clone 35) was chosen for further
experiments. The cells were seeded in 6-well plates
(210
5/well) the day before transfection. One microgram
of each plasmid (pEF-VLVP16 alone or pEF-VLVP16
plus pEF/myc/nuc/VH#6) was co-transfected and 48h
later, the cells were harvested, washed and resuspended
in PBS. The GFP reporter ﬂuorescence expression was
measured with a FACSCalibur and the data were ana-
lyzed using FCSPress software.
Mammalian luciferase reporter assays were performed
as described (11). pM-Ag bait (0.2mg), 0.2mg pEF-
VLVP16 prey and 0.2mg pEF/myc/nuc/VH catcher plas-
mids were transiently co-transfected with the reporter
plasmid 0.2mg pG5-Luc and 0.02mg pRL-CMV
(Promega) into COS-7 cells in 12-well plates (410
4/
well) using lipofectamine. After 48h, the cells were lysed
and assayed by the dual-luciferase reporter system
(Promega) in a luminometer.
Protein expression and purification
To co-express recombinant proteins in bacteria, VH#6,
HRAS(G12V) and VL (VLI21 or VL#204), the bacterial
tri-cistronic expression vector, pRK-HISTEV-VH-RAS-
VL (diagrammatically shown Figure 3C) (18) was trans-
formed into the C41(DE3) bacterial host, grown to an
OD600 of 0.6 and induced with IPTG (ﬁnal 0.5mM) at
378C for 4h. The proteins were extracted from bacteria
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buﬀer (25mM Na phosphate, pH 7.4, 300mM NaCl and
20mM imidazole) and proteins co-puriﬁed using His-Trap
Ni-aﬃnity columns (GE Healthcare) using gradient
elution with 20–300mM imidazole histidine analog. The
puriﬁed proteins were analyzed by SDS–PAGE and visua-
lized by staining Coomassie brilliant blue.
For puriﬁcation of GST fusion protein, pGEX-
HRAS(G12V) or pGEXHISTEV-LMO2 were trans-
formed into C41(DE3). The GST-RAS puriﬁcation was
performed as described elsewhere (18). For GST-LMO2,
cells were grown at 378Ct oa nO D 600 of 0.6, ZnSO4 was
added to a ﬁnal concentration of 100mM and protein
induced with 0.5mM IPTG at 168C for 14h. The soluble
proteins were extracted, and the GST-LMO2 was bound
to glutathione-sepharose. Soluble GST-LMO2 was eluted
with 50mM Tris–HCl pH 8.0, 10mM reduced glu-
tathione, 150mM NaCl and 0.05mM ZnSO4.
For puriﬁcation of anti-RAS scFv, the plasmid pRK-
HISTEV-scFv was prepared by sub-cloning scFv into
pRK172 as described elsewhere (11).
Affinity measurement bysurface plasmonresonance
The binding kinetics of antibody fragments were measured
using a BIAcore 2000 or 3000 (Biacore) as described (11).
GST or GST-HRAS(G12V)-GTPgS or GST-LMO2 were
captured on a CM5 sensor chip (Biacore) through immo-
bilized anti-GST polyclonal antibody (GE Healthcare).
Aﬃnity measurements for anti-RAS or anti-LMO2 scFv
were performed by injection of puriﬁed proteins with var-
ious concentrations (0.5nM–1000nM) in 20mM Tris–
HCl, pH 8.0, 100mM NaCl, 5mM MgCl2 and 0.005%
Tween 20 or in HBS-EP buﬀer (Biacore). Evaluation
and calculation of the binding parameters were carried
out according to the BIA evaluation 2.1 software.
Immunoprecipitation
For immunoprecipitation assays with anti-RAS scFv,
NIH 3T3 ﬁbroblasts were maintained in DMEM contain-
ing 10% foetal calf serum (FCS). For serum stimulation
of RAS expression, cells were washed with serum-
free medium and incubated in DMEM without serum
for 24h before re-introduction of 10% calf serum. Cells
were harvested at various times after serum treatment. For
the assay with anti-LMO2 scFv, pEF-BOS-LMO2-myc
(19) was transiently transfected into CHO cells. After
72h, the cells were washed three times with ice-cold PBS
and lysed in buﬀer-containing 50mM HEPES (pH 7.5),
150mM NaCl, 1mM EDTA, 10mM MgCl2, 1% NP-40
and 10% glycerol for 30min on ice. Lysates were either
used immediately or frozen in liquid nitrogen and stored
at –708C until use. For immunoprecipitations, the lysate
was mixed with puriﬁed His-tagged anti-RAS scFv
(VH#6-VL#204), anti-LMO2 scFv (VH#576-VL#826) or
scFv (VH#576-VL#827) and Ni-NTA agarose beads
(Qiagen) and mixed by rotation for 30min at 48C. The
mixture was centrifuged brieﬂy, the supernatant discarded
and the agarose pellets washed at least ﬁve times
with PBS. The beads were ﬁnally resuspended in SDS–
PAGE buﬀer and the solubilized proteins separated by
SDS–PAGE and transferred to membranes by western
blotting. The membranes were incubated with anti-pan
RAS (Ab-3, Calbiochem) antibody for RAS protein detec-
tion or anti-myc (9E10, Sigma) antibody for LMO2 pro-
tein detection and the bound antibody visualized using
peroxidase-conjugated anti-mouse IgG antibody and
detected by ECL (GE Healthcare).
RESULTS
Outline ofthe CatcherAb method
The objective was to develop a screening procedure for
isolation of single-domain intrabodies (i.e. variable
domains of the heavy chain, VH, and variable domains
of the light chain, VL) that bind to the same epitopic
region on an antigen. The CatcherAb approach, schemat-
ically shown in Figure 1A, comprises selecting an antigen-
speciﬁc VL single domain as a prey via enhanced binding
to antigen bait, facilitated by tertiary interaction with an
antigen-speciﬁc VH domain (Catcher) (Figure 1A, Step 1).
The essence of the CatcherAb method is that the VL prey
does not have suﬃcient aﬃnity to be selected through
binding to the antigen bait alone in the in vivo system
and must be strengthened by the interaction with the anti-
gen bait through the complementary VH.
Two VL-VP16AD yeast libraries served as the initial
libraries for the Catcher method. These diverse libraries
were transfected into yeast co-expressing a LexA-DBD-
antigen bait and a Catcher VH segment (Supplementary
Figure S1) and antigen-speciﬁc clones isolated using selec-
tive media. These clones comprise VL that bind to the
same epitopic region on the bait as does the cognate
Catcher VH. Low-aﬃnity binders were eliminated by
growth of the selected clones on histidine-minus medium
with increasing concentrations of the histidine biosynthe-
sis inhibitor, 3-AT. In some cases, the ﬁrst VL clones were
pooled and further CDR randomization carried out
(Figure 1A, optional step) followed by a re-screen in the
bait yeast strain with a Catcher VH. Finally, VL comple-
mentary to the Catcher VH was conﬁrmed using a mam-
malian transfection assay (Figure 1A, Step 2). Figure 1B
shows the amino-acid sequence of the VL libraries with
the indicated CDR changes in the initial and second form.
Isolationof anti-RAS complementary VL
First-round yeast screens were carried out with the two
VL iDab libraries in L40-ura3 expressing the bait LexA-
HRAS(G12V) and VH#6 and 40 million transfected cells
were selected on Trp, Leu, Ura and His-minus plates with
increasing 3-AT concentrations. As expected, increasing
3-AT levels in the media severely aﬀected the number of
colonies and no colonies appeared on plates with 75mM
3-AT or more (Figure 2A). Twenty clones were selected
from the colonies growing on plates containing 20–50mM
3-AT. Interaction of the bait and prey was conﬁrmed by
tested b-gal expression (using the recovering bait plasmid)
and b-gal expression was found in nine clones derived
from VL-I and 17 from VL-J. The diversity of the VL
sequences was determined by sequencing (sequences
shown in Supplementary Figure S2) and six clones were
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concentrations. These clones were pooled and the CDR1
randomized by PCR and fragment assembly (16) to gen-
erate a second-round VL-VP16 library of 1.2 million
clones. This library was screened again by the
CatcherAb method and 40 clones were sequenced (all 10
that grew at 150mM 3-AT and 30 from growth at 100mM
3-AT), and the sequences of 16 are shown Supplementary
Figure S2. The variation in the ability of several ﬁrst- and
second-round VL clones to support growth in the yeast
three hybrid (Y3H) assay in the absence of histidine is
shown in Figure 2B. Whilst yeast expressing round one
CDR1 CDR2 CDR3
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLN WYQQKPGKAPKLLIYXASXLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQXXXXPXTFGQGTKVEIKR
DIQMTQSPSSLSASVGDRVTITCRASQXIXXXLN WYQQKPGKAPKLLIYXASXLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQXXXXPXTFGQGTKVEIKR
A
B
Screen VH single domain library in yeast using Intracellular Antibody Capture (IAC)
Antigen-specific VH Catcher antibody
Screen VL library in yeast by IAC in presence of the VH Catcher antibody
Isolate VL antigen binders by growth on histidine-minus plates
Rescue VL plasmids from yeast 
Identify complementary VL in yeast by growth with bait +/- Catcher antibody 
Antigen-specific VL complementary to VH Catcher antibody 
Confirm VL-VH complementary binding to antigen in mammalian cells
Antigen-specific VL complementary to the VH Catcher antibody
DBD-antigen bait + VL-VP16 library prey
             + VH Catcher antibody
DBD-antigen bait + VL-VP16 prey
          +/- VH Catcher antibody
DBD-antigen bait + VL-VP16 prey
             + VH Catcher antibody
STEP 1:
STEP 2:
Pool VL binders & 
use PCR-based
  CDR diversifica-
tion (maturation) 
(Optional 
step) 
Figure 1. CatcherAb for selecting complementary single domains. The method relies on the isolation of antigen-speciﬁc immunoglobulin single
domains dependent on simultaneous interaction of VH and VL with antigen. (A) A ﬂow diagram of the CatcherAb screening method for selecting
VL binders complementarily with VH. Initially, a single VH domains is selected with intracellular antibody capture methods (IAC) as the Catcher
antibody. In Step 1, yeast expressing an antigen bait and the Catcher antibody are screened with a diverse VL prey library. Selected clones can
(optional) be pooled, further randomized and rescreened in the Catcher system or taken directly into Step 2, where the VL-VH complementarity is
conﬁrmed. (B) Amino-acid sequences (single-letter code) of the two diversiﬁed human VL libraries (CDR regions highlighted). The VL library from
the ﬁrst screening (shown in the top line) was made from the synthetic human scFv phage libraries I or J (15) by PCR of the VL segments and
cloning into pVP16 (13). The VL library for the second screening, where necessary (bottom line), was constructed from VL DNA of the CatcherAb
selected clones from initial screening and diversiﬁed by PCR assembly (16) (diversiﬁcation was accomplished for CDR1, four positions; CDR2, two
positions; CDR3, ﬁve positions, indicated by X).
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none of the round one clones grew at 160mM 3-AT. On
the other hand, all six of the second-round VL clones
supported growth at 80mM 3-AT and three grew robustly
under the strong selection of 160mM 3-AT.
Anti-RAS scFv comprising of anti-RAS VH and
complementary VL
The requirement for the VH-RAS interaction to achieve
VL binding to antigen was conﬁrmed using a mammalian
three hybrid reporter assay using CHO-GFP-HRAS cells
carrying a Gal4 DNA binding site-GFP reporter gene (11)
and expressing Gal4DBD-HRAS(G12V) fusion antigen
bait). No GFP activation occurred with any of the selected
VL segments expressed as VL-VP16 fusions in these repor-
ter cells (Figure 3A), whereas variable amounts of GFP
ﬂuorescence could be detected by ﬂow cytometry when the
reporter cells were co-transfected with VL-VP16 and the
Catcher VH (Figure 3B), VL#204 showed the greatest
stimulation. We conclude that the anti-RAS VL single
domains only bind to antigen suﬃciently when in the pres-
ence of VH#6 by the formation of a trimeric complex.
The physical association of VH, VL and antigen was
veriﬁed by co-expressing recombinant RAS, anti-RAS
VH#6 and VL#206 in the cytoplasm of bacteria using a
tricistronic vector and purifying the complex directly by
aﬃnity chromatography via a histidine tag on the VH#6
segment (Figure 3C). All three recombinant proteins were
synthesized in soluble form at 378C and co-puriﬁed with
the VH on nickel–agarose. The yields of the puriﬁed pro-
teins were more than 4mg/l of culture, showing that both
VH and VL single domains are stable, fold properly and
function in antigen binding inside cells under natural
human body temperatures.
The VH#6 and VL#204 were formulated into an scFv
molecule and in vitro aﬃnity measurements determined
by surface plasmon resonance (SPR). The equilibrium
dissociation constant (Kd) was determined at 0.3nM,
which is 36 times better than a combination of VH#6
and non-relevant VLI21) (Figure 3D).
To evaluate the use of the anti-RAS antibody (scFv)
derived from the CatcherAb screening in immunoprecipi-
tations, the recombinant anti-RAS scFv antibody (com-
prising VH#6 and VL#204 with a linker peptide) was
used to immunoprecipitate endogenous activated RAS
expressed after serum-stimulation of ﬁbroblasts. A time
course of serum stimulation of NIH3T3 cells was carried
out and the newly produced, activated RAS was immuno-
precipitated with the scFv and separated by SDS–PAGE,
followed by western detection using an anti-pan RAS
antiserum (Figure 3E).
Complementary VH and VLanti-LMO2 singledomains
The generation of eﬀective and speciﬁc antibodies binding
to native LMO2 has proven diﬃcult. We applied the
CatcheAb method to generate an anti-LMO2 scFv able
to immuno-precipitate native LMO2 from mammalian
cells. We have developed an anti-LMO2 VH using IAC
selection (VH#576, TT and THR unpublished results),
and this was used for our CatcherAb screening. After
ﬁrst-round screening, several yeast clones were isolated
that could grow on plates with stringent 3-AT conditions
(Figure 4A). These clones were compared by DNA
sequence analysis and this showed that 20 diﬀerent VL
sequences had been selected (shown in Supplementary
Figure S3).
In particular, it was noted that the CDR3 region
showed great variability and, thus selected clones were
screened directly in the mammalian luciferase reporter
-WLUH
-WLUH+10mM3AT
-WLUH+20mM3AT
-WLUH+30mM3AT
-WLUH+50mM3AT
-WLUH+75mM3AT
-WLUH+100mM3AT
-WLUH+150mM3AT
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>200
35
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3
3
0
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28
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7
2
0
No. of HIS positive clones
Growth conditions 2nd round
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A B
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VH#6 Y13-
293
cRAF
RBD ATF2
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Figure 2. Isolation of complementary anti-RAS VL single domains by the CatcherAb method. (A) Two VL-VP16 libraries were screened with a RAS
bait and the anti-RAS VH#6 CatcherAb and positive clones assessed by growth in the absence of Trp, Leu, Ura and His (–WLUH), with increasing
concentrations of 3-AT. After the second round of selection, improved aﬃnity of VL binding was achieved by PCR diversiﬁcation using six of the
ﬁrst-round clones that grew on plates supplemented with between 30 or 50mM 3-AT. The pooled library was re-screened in a second round and
clones selected by growth in the absence of WLUH and with 75, 100 or 150mM 3-AT. (B) Veriﬁcation of complementary antigen binding was
obtained by co-transfecting the LexA-HRAS(G12V) bait, pCatcher-VH#6 and VL-VP16 fusion vectors into yeast L40-ura3 cells. The transfected
yeast was patched, grown on selective master plates (WLU or WLUH) and replicated on WLUH plates supplemented with 80 or 160mM 3-AT.
The bottom panel shows the key for clone locations on the master plates. cRAF-RBD-VP16 (11), Y13-293-VP16 (17) and VH#6-VP16 (18) were used
as positive controls and ATF-2-VP16 as negative control, respectively, for binding with the RAS bait.
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VL segments were tested in the assay in which the VL
prey was co-expressed with an LMO2 bait and the anti-
LMO2 VH#576 segment (Figure 4B) or with the anti-RAS
VH#6 as a negative binding control (Figure 4C).
Nine of the anti-LMO2 VL showed direct binding
to LMO2, because the luciferase activation was not depen-
dent on co-expression of the anti-LMO2 Catcher VH
and three VL segments activated the luciferase reporter
in a Catcher VH#576-dependent fashion (Figure 4B).
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Figure 3. Interaction of RAS, VH and VL. (A and B) Flow cytometry of CHO-GFP reporter cells expressing the Gal4DBD-RAS bait and the
indicated VL-VP16 prey only (A) or cells expressing the RAS bait, VL-VP16 prey plus the VH#6 Catcher antibody (B). The x-axis shows the
ﬂuorescence intensity and the percentages shown indicate the proportion of cells in the transfected populations expressing GFP. (C) Bacterial
expression and co-puriﬁcation of RAS, anti-RAS VL and anti-RAS VH. Diagram of the tri-cistronic vector, pRK-HISTEV-VH-RAS-VL, for
co-expressing the anti-RAS VH#6, HRAS(G12V) antigen is shown (bottom). Expressed proteins (VH#6, HRAS and VL) were co-puriﬁed by
Ni-aﬃnity column using the His-tag on the VH#6 protein, fractionated on SDS–PAGE gels and stained with Coomassie Brilliant Blue. Lane 1:
molecular weight markers; lane 2, puriﬁed proteins expressed from pRK-HISTEV-VH#6-RAS-VLI21; lane 3, puriﬁed proteins were expressed from
pRK-HISTEV-VH#6-RAS-VL#204. (D) The binding aﬃnities of engineered scFv were determined by SPR. (E) Detection of native GTP-bound RAS
by the anti-RAS scFv (VH#6-VL#204). NIH3T3 cells were serum starved and treated with 10% FCS for the times indicated. Endogenous, activated
RAS protein was immunoprecipitated (IP) from the cells with His-tagged scFv VH#6-VL#204 protein and bound RAS protein recovered on Ni-NTA
agarose. Recovered RAS was subjected to SDS–PAGE, immunoblotted for detection with an anti-pan RAS antibody (Ab-3, Calbiochem).
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the binding aﬃnity determined using SPR. The scFv
(VH#576-VL#826) showed a Kd of 4.3nM (Figure 4D)
compared with a Kd of 94nM for the VH#576 coupled
to the non-relevant VLI21.
The ability of the anti-LMO2 scFv recombinant pro-
teins (VH#576 with either VL#826 or with VL#827) to
detect native LMO2 protein was determined in a biochem-
ical application. Transient expression of LMO2, with a
myc-epitope tag, was carried out in CHO cells. The pro-
tein from these cells was immuno-precipitated with either
the VH#576-VL#826, VH#576-VL#827 anti-LMO2 scFv
or the anti-RAS scFv as negative control. The recovered
LMO2 protein was identiﬁed by western detection of the
myc-tag present on the LMO2 (Figure 4E).
DISCUSSION
The use of the IAC method to select single domains in vivo
(11) is useful for the production of high aﬃnity and func-
tional intracellular antibody fragments, which can be used
to target and validate disease target molecules [see,
for example, ref. (18)]. Conversion of these antibody frag-
ments into scFv (and also to full antibody) has many
potential uses beyond intracellular antibody studies,
including laboratory procedures that require binding to
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Figure 4. Anti-LMO2 VL complementary single domains. (A) VL-I and VL-J libraries were screened with an LMO2 bait and the anti-LMO2 VH576
CatcherAb and positive clones assessed on –WLUH plates, with increasing concentrations of 3-AT as indicated. (B and C) Luciferase reporter assays
for anti-LMO2 VL binding. COS-7 cells were transiently transfected with plasmids expressing the individual prey VL-VP16 fusion proteins (shown
on the x-axis) together with (B) the pM-dLMO2 bait plus pEF/myc/nuc/VH#576 (anti-LMO2 catcher VH) or (C) the pM-dLMO2 plus pEF/myc/
nuc/VH#6 (anti-RAS catcher VH), together with luciferase reporters. Luciferase activities were measured after 48h. Normalized fold ﬁreﬂy and
renilla luciferase inductions are shown as the mean  SEM of four individual experiments. The luciferase activity after co-transfecting pM-dLMO2
with pEF-VH#6-VP16 was used as negative control for normalization. (D) The aﬃnities of engineered scFv binding with LMO2 were determined by
surface plasmon resonance. (E) Immunoprecipitation of LMO2 protein using anti-LMO2 scFv (VH#576-VL#826) or scFv(VH#576-VL#827)
recombinant proteins. CHO cells were transfected with plasmids expressing a myc-tagged LMO2 or were mock-transfected and lysed after 72h.
LMO2 protein was immunoprecipitated with HIS-tagged scFv and precipitated material recovered by binding to Ni-NTA agarose. Bound LMO2
protein was detected by immunoblotting with anti-myc monoclonal antibody (9E10).
PAGE 7 OF 8 Nucleic AcidsResearch, 2009, Vol.37,No. 5 e41native proteins such as ﬂow cytometry. In order to facil-
itate this objective, we have described a simple method
for selecting complementary single domains to existing,
characterized iDabs.
The reagents produced with a combination of IAC and
CatcherAb technologies recognize native protein antigens
and can be engineered into scFv, which could in turn be
made into whole antibodies if required. The interaction of
single domains at the same location (epitopic region) on a
target antigen can also be used to bring close together
cargoes that might be required to activate other pathways
within cells (20) or to serve as pro-drugs. The importance
of monoclonal antibodies in modern biological research
is apparent from the range of laboratory techniques that
use antibodies corresponding to diﬀerent species (mouse,
rat, human, etc.). In addition, the importance in modern
medicine is apparent with the successes of chimaeric
mouse-human antibodies [e.g. anti-TNF inﬂiximab (21)
or anti-CD20 Rituximab (22)] or of humanized mouse
monoclonal antibodies [e.g. anti-HER2 Trastuzumab
(23)], and the potential cannot be over-stated. Simple
methods that do not require animal immunizations, such
as phage display, and that can be tailored to speciﬁc tar-
gets should increase the versatility and eﬃcacy of these
reagents. An additional advantage of the CatcherAb tech-
nique allows isolation of antibodies that bind to native
protein antigens (thus fragments of extracellular proteins
could be used as antigen in this approach). Further only
requires the knowledge of the primary DNA sequence to
engineer an in vivo expression clone to develop the anti-
body. In this way, proteins that cannot easily be made in
recombinant, soluble form will be targetable by this
approach giving a ﬂexible platform from which to develop
a range of antibodies.
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